A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

dc.contributor.author	Valladares Ayerbes, Manuel
dc.date.accessioned	2017-06-07T07:06:51Z
dc.date.available	2017-06-07T07:06:51Z
dc.date.issued	2011
dc.identifier.issn	0167-6997
dc.identifier.uri	http://hdl.handle.net/20.500.11940/2745
dc.language.iso	eng
dc.title	A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
dc.type	Artigo	es
dc.authorsophos	Bennouna, J.
dc.authorsophos	Lang, I.
dc.authorsophos	Valladares-Ayerbes, M.
dc.authorsophos	Boer, K.
dc.authorsophos	Adenis, A.
dc.authorsophos	Escudero, P.
dc.authorsophos	Kim, T. Y.
dc.authorsophos	Pover, G. M.
dc.authorsophos	Morris, C. D.
dc.authorsophos	Douillard, J. Y.
dc.identifier.doi	10.1007/s10637-010-9392-8
dc.identifier.pmid	20127139
dc.identifier.sophos	9003
dc.issue.number	5
dc.journal.title	INVESTIGATIONAL NEW DRUGS
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Oncoloxía médica
dc.page.initial	1021
dc.page.final	1028
dc.rights.accessRights	openAccess
dc.typesophos	Artículo Original
dc.volume.number	29

Files in this item

Files	Size	Format	View
There are no files associated with this item.